Predicting Dropout and Outcome From Neuropsychological Functions in SUD Patients

Active, not recruiting

• Conditions: Substance Use Disorder (SUD)

• Registration Number: NCT03220373
• Lead Sponsor: Oslo University Hospital

Brief Summary

The aim of this project is to gain a more specific understanding of how different cognitive profiles predict residential treatment drop-out, treatment retention and post-treatment outcome in a population with Substance Use Disorder.

Detailed Description

This project collects the neuropsychological profile of residential SUD patients, in addition to treatment length, exit reason, hospital journal data and post-treatment clinical outcome data. The project aims to identify clinically relevant neurocognitive domains that predict treatment dropout and post-treatment clinical outcome. This will make it possible for future clinicians to focus their effort on neurocognitive functions most relevant for this particular patient group.

RESEARCH QUESTIONS:

1. What neurocognitive domain (and sub-domain) are the strongest predictor of treatment drop-out and retention?

2. What neurocognitive domain (and sub-domain) are the strongest predictor of post-treatment clinical outcome variables such as drug use, health and social integration.

3. Will data on treatment length, age, gender, substance abuse history or psychiatric co-morbidity predict outcome independently, or in interaction with, the neuropsychological profile?

This longitudinal prospective cohort study aims for a continuous collection of neuropsychological data baseline and post-treatment follow-up data until 2030.

Study Timeline

• Study Start: 2017-03-07
• Study First Submitted: 2017-03-08
• Study First Submitted QC: 2017-07-16
• Study First Posted: 2017-07-18
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-03
• Last Update Posted: 2024-01-05
• Primary Completion: 2029-12-31
• Study Completion: 2029-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Substance Use Disorder (SUD) patients.
• 18 years or older.
• Qualified to consent to research participation.
• Able to speak and write in Norwegian.

Exclusion Criteria

• Not qualified to consent to research participation.
• Insufficient understanding of Norwegian.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Exit reason	On average 3 months	Reason for terminating residential SUD treatment (Treatment completed or Drop-out)
Treatment retention	On average 3 months	Number of days in treatment

Secondary Outcome Measures

Name	Time	Method
Quality of Life	1 year after neuropsychological assessment	QoL-5 (Quality of Life)
Substance use	1 year after neuropsychological assessment	DUDIT (Drug Use Disorders Identification Test)
Psychological distress	1 year after neuropsychological assessment	SCL-10 (Symptom Checklist)
Income	1 year after neuropsychological assessment	Nature of income
ADHD symptoms	1 year after neuropsychological assessment	ASRS (ADHD Self-Report Scale)
Housing	1 year after neuropsychological assessment	Nature of present accommodation

Trial Locations

Locations (1)

Oslo University Hospital; 🇳🇴 Oslo, Norway